Clinical Trial Detail

NCT ID NCT02000882
Title Capecitabine + BKM120 TNBC BC Brain Met
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors US Oncology Research
Indications

triple-receptor negative breast cancer

Therapies

Buparlisib + Capecitabine

Age Groups: adult

No variant requirements are available.